Indication: Indicated for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
Table of Contents

Abbreviations ............................................................................................................. 5

Executive Summary ..................................................................................................... 6
  Conclusions ................................................................................................................... 8

Stakeholder Input Relevant to the Economic Review .................................................... 9

Economic Review ......................................................................................................... 9
  Economic Evaluation .................................................................................................... 9
  Issues for Consideration ............................................................................................... 19
  Overall Conclusions .................................................................................................... 20

Appendix 1: Cost Comparison Table ............................................................................ 21

Appendix 2: Submission Quality ................................................................................... 25

Appendix 3: Additional Information on the Submitted Economic Evaluation .......... 26

Appendix 4: Additional Details on the CADTH Reanalyses and Sensitivity Analyses of the Economic Evaluation ................................................................. 28

References ..................................................................................................................... 30

Tables

Table 1: Submitted for Review ....................................................................................... 6
Table 2: Summary of Economic Evaluation .................................................................. 7
Table 3: Summary of the Sponsor’s Economic Evaluation Results ................................ 12
Table 4: Key Assumptions of the Submitted Economic Evaluation ................................. 15
Table 5: CADTH Revisions to the Submitted Economic Evaluation ............................... 16
Table 6: Summary of the Stepped Analysis of the CADTH Reanalysis Results .......... 17
Table 7: Disaggregated Summary of the CADTH Economic Evaluation Resultsa .......... 18
Table 8: CADTH Price-Reduction Analyses .................................................................. 18
Table 9: CADTH Cost Comparison Table for Systemic Treatments for Atopic Dermatitis ......................................................................................................................... 21
Table 10: CADTH Cost Comparison Table for Topical Treatments for Atopic Dermatitis ......................................................................................................................... 22
Table 11: Submission Quality ......................................................................................... 25
Table 12: Probabilistic Results of Sponsor’s Base-Case Analysis .................................. 27
Table 13: Probabilistic Results of Sponsor’s Scenario Analyses ....................................... 27
Table 14: Probabilistic Results of the CADTH Scenario Analyses ................................... 28
Table 15: Additional CADTH Price-Reduction Analyses – Reimbursement-Request Population .................................................................................................................. 28
Table 16: Probabilistic results of the CADTH Exploratory Analyses by Disease Severity ......................................................................................................................... 29
Figures

Figure 1: Decision Tree .......................................................... 26
Figure 2: Markov Structure.......................................................... 26
### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AD</td>
<td>atopic dermatitis</td>
</tr>
<tr>
<td>DUP</td>
<td>dupilumab</td>
</tr>
<tr>
<td>EASI</td>
<td>Eczema Area and Severity Index</td>
</tr>
<tr>
<td>EASI-50</td>
<td>Eczema Area and Severity Index score improvement from baseline ≥ 50%</td>
</tr>
<tr>
<td>EASI-75</td>
<td>Eczema Area and Severity Index score improvement from baseline ≥ 75%</td>
</tr>
<tr>
<td>ICER</td>
<td>incremental cost-effectiveness ratio</td>
</tr>
<tr>
<td>EQ-5D</td>
<td>EuroQol 5-Dimensions</td>
</tr>
<tr>
<td>SOC</td>
<td>standard of care</td>
</tr>
<tr>
<td>QALY</td>
<td>quality-adjusted life-year</td>
</tr>
</tbody>
</table>
Executive Summary

The executive summary comprises two tables (Table 1: Submitted for Review and Table 2: Summary of Economic Evaluation) and a conclusion.

Table 1: Submitted for Review

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug product</td>
<td>Dupilumab (Dupixent), 200 mg or 300 mg single-use syringe with a needle shield or pre-filled syringes in packs of 1 or 2</td>
</tr>
<tr>
<td>Submitted price</td>
<td>Dupilumab, 200 mg, subcutaneous injection: $959.94 per pack of 1</td>
</tr>
<tr>
<td></td>
<td>Dupilumab, 300 mg, subcutaneous injection: $959.94 per pack of 1</td>
</tr>
<tr>
<td>Indication</td>
<td>For the treatment of patients aged ≥ 12 years with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable</td>
</tr>
<tr>
<td>Health Canada approval status</td>
<td>NOC</td>
</tr>
<tr>
<td>Health Canada review pathway</td>
<td>Standard review</td>
</tr>
<tr>
<td>NOC date</td>
<td>25-09-2019</td>
</tr>
<tr>
<td>Reimbursement request</td>
<td>Patients aged ≥ 12 years with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable, and/or who are refractory to or ineligible for systemic immunosuppressant therapies (i.e., due to contraindications, intolerance, or need for long-term treatment)</td>
</tr>
<tr>
<td>Sponsor</td>
<td>Sanofi Genzyme, a division of sanofi-aventis Canada Inc.</td>
</tr>
<tr>
<td>Submission history</td>
<td>Previously reviewed: Yes</td>
</tr>
<tr>
<td></td>
<td>Indication: Adult patients with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable</td>
</tr>
<tr>
<td></td>
<td>Recommendation date: June 27, 2018</td>
</tr>
<tr>
<td></td>
<td>Recommendation: Do not reimburse</td>
</tr>
</tbody>
</table>

AD = atopic dermatitis; NOC = Notice of Compliance.
### Table 2: Summary of Economic Evaluation

<table>
<thead>
<tr>
<th>Component</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type of economic evaluation</strong></td>
<td>Cost-utility analysis</td>
</tr>
<tr>
<td><strong>Target population</strong></td>
<td>Patients aged ≥ 12 years with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>DUP + SOC (topical therapy&lt;sup&gt;b&lt;/sup&gt;)</td>
</tr>
<tr>
<td><strong>Comparator</strong></td>
<td>SOC</td>
</tr>
<tr>
<td><strong>Perspective</strong></td>
<td>Canadian publicly funded health care payer</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>QALYs, life-years</td>
</tr>
<tr>
<td><strong>Time horizon</strong></td>
<td>Lifetime (86 years)</td>
</tr>
<tr>
<td><strong>Key data sources</strong></td>
<td>AD-1526, SOLO 1, SOLO 2, LIBERTY AD CHRONOS, LIBERTY AD CAFÉ trials</td>
</tr>
</tbody>
</table>
| **Submitted results for base-case and key scenario analyses** | Base case: patients whose disease is not adequately controlled with topical prescription therapies, or for whom those therapies are not advisable  
  - ICER = $50,133 per QALY (incremental cost = $127,607; incremental QALYs = 2.55)  
  Key scenario analysis:  
  - Patients who could no longer use systemic immunosuppressant therapies (reimbursement-request population: ICER = $52,168 per QALY)                                                                                       |
| **Key limitations**                |  
  - Relevant comparators, such as immunosuppressants (e.g., methotrexate and cyclosporine), are prescribed to treat moderate-to-severe AD but are not included as comparators in the model.  
  - The sponsor assumed data from clinically different patient populations could be combined to follow patients throughout the model. CADTH did not consider this application of data to be appropriate.  
  - The clinical data indicate that DUP’s efficacy differs based on disease severity; this impact could not be assessed by CADTH given differences between the available clinical data and outcomes assessed in the model. Exploratory analyses highlighted that duration of benefit between weeks 16 and 52 appeared to be a more important driver of the results than treatment response at week 16.  
  - The sponsor incorporated treatment-specific utility values, which do not reflect best practices. Further, the methodology used to derive these values was associated with substantial uncertainty.  
  - The utility estimates lacked face validity in several respects: the baseline utility score was notably lower than those reported in other HTA appraisals, the utility weight for DUP + SOC responders was higher than Canada’s EQ-5D population norm, and data from distinctly different populations were used, which resulted in an implausible age-related decrease in utility between ages 18 and 19.  
  - The inclusion of caregiver disutilities in the base case does not align with the public payer perspective methodology.  
  - The durability of treatment response beyond the trial duration remains uncertain; however the incremental benefit of DUP + SOC compared with SOC appeared to be overestimated.  
  - The sponsor incorporated expert-elicited frequencies of resource use that do not align with Canadian clinical practice based on feedback from the clinical expert consulted by CADTH for this review.                                                                                                                                 |
| **CADTH reanalysis results**       |  
  - The CADTH reanalysis included the exclusion of caregiver utilities; alternate measures for treatment response, utility, durability of response; and a macro-level costing approach. CADTH identified other limitations that could not be assessed in reanalyses.  
  - ICER: $136,025 per additional QALY gained (1.26 incremental QALYs, $171,694 incremental costs).                                                                                                                                                  |
The results in the indicated population warrant careful interpretation as 95% of DUP + SOC’s incremental benefit was accrued during time points beyond which clinical data are available.

A price reduction of 54% was required for DUP + SOC to achieve an ICER below $50,000 per QALY gained.

CADTH undertook a scenario analysis in the reimbursement-request population, which resulted in a similar ICER ($133,877 per QALY gained).

**Conclusions**

CADTH undertook reanalyses to address limitations relating to the application of treatment effects, utility estimates, resource use, and long-term durability of treatment effects.

Following reanalysis of the Health Canada–indicated and reimbursement-request populations, CADTH estimated the corresponding incremental cost-effective ratios for dupilumab (DUP) plus SOC versus SOC alone to be $136,025 per additional quality-adjusted life-year (QALY) gained and $133,877 per QALY gained for the Health Canada–indicated population. A reduction of 54% in DUP’s price was required to improve its cost-effectiveness, relative to SOC, in both populations and generate an incremental cost-effectiveness ratio of less than $50,000 per QALY. The results for the reimbursement request population were similar.

The results of the CADTH reanalysis remain uncertain as multiple limitations could not be addressed. CADTH was unable to assess the cost-effectiveness of DUP + SOC compared to alternative comparators that are presently used by patients with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies; nor was it possible to determine how DUP’s cost-effectiveness differed in patients with moderate AD versus those with severe AD. Additional scenario and exploratory analyses were undertaken that highlighted the uncertainty associated with the assumptions for durability of effect for DUP + SOC and SOC alone.

<table>
<thead>
<tr>
<th>Component</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• The results in the indicated population warrant careful interpretation as 95% of DUP + SOC’s incremental benefit was accrued during time points beyond which clinical data are available.</td>
</tr>
<tr>
<td></td>
<td>• A price reduction of 54% was required for DUP + SOC to achieve an ICER below $50,000 per QALY gained.</td>
</tr>
<tr>
<td></td>
<td>• CADTH undertook a scenario analysis in the reimbursement-request population, which resulted in a similar ICER ($133,877 per QALY gained).</td>
</tr>
</tbody>
</table>

AD = atopic dermatitis; DUP = dupilumab; EQ-5D = EuroQol 5-Dimensions; HTA = health technology assessment; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year; SOC = standard of care.

a A secondary study objective was to assess the cost-effectiveness of DUP + SOC versus SOC in patients aged 12 years and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable and/or who are refractory to or ineligible for systemic immunosuppressant therapies.

b The sponsor did not indicate which topical therapies were included in the standard of care treatment for moderate-to-severe AD.
Stakeholder Input Relevant to the Economic Review

This section is a summary of the feedback received from the patient groups that participated in the CADTH review process as the information pertains to the economic submission.

Two patient groups contributed to the CADTH appraisal of the sponsor’s pharmacoeconomic analysis of dupilumab.1

The patients expressed a desire for flare prevention and the elimination of AD-related symptoms (e.g., itching, burning, pain, open sores, sleep disturbance, anxiety and depression) as the overarching goals of treatment. The development of such outcomes may reduce the condition’s impacts on quality of life that the patients noted: itching, pain, loss of productivity, social isolation, interrupted sleep, mood changes, poor self-esteem, loss of energy, increased stress, and suicidal thoughts. Among adolescents, the three primary issues were avoidance of social activities, inability to participate in sports and physical activities, and interrupted sleep. Patients who were treated with dupilumab (DUP) reported improvements in their disease symptoms and quality of life. The sponsor modelled the costs associated with incident skin infections, which likely encompassed some of the AD-related symptoms identified by patients.

The sponsor accounted for caregiver utility and productivity loss in its scenario analyses, but did not explore other key considerations identified by patients (e.g., out-of-pocket expenses for mental health services and transportation costs).

Economic Review

The current review is for DUP (Dupixent) plus SOC; i.e., unspecified topical therapy) compared to SOC alone for patients aged ≥ 12 years with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable.

Economic Evaluation

Summary of Sponsor’s Economic Evaluation

Overview

The sponsor submitted a cost-utility analysis of DUP plus SOC (DUP + SOC) versus SOC.1 The model population comprised patients aged 12 years or older with moderate-to-severe AD for whom topical prescription therapies failed to achieve effective disease control or were not advisable. This population was consistent with the Health Canada–indicated population. However, the sponsor’s reimbursement request also included patients who are refractory to, or ineligible for, systemic immunosuppressant therapies due to contraindications, intolerance, or a need for long-term treatment.2 To address these patients, the sponsor conducted analyses in subgroups of those who could no longer take systemic immunosuppressant therapies (e.g., methotrexate and cyclosporine) with additional age criteria. The trial of DUP in adolescents (AD-1526) assessed patients with moderate-to-severe AD who had demonstrated a recent history of inadequate response to topical therapies or for whom topicals were not advised (due to intolerance, side effects, or safety risks) and excluded patients who had been treated with immunosuppressants, immunomodulators, or phototherapy within four weeks of baseline. This exclusion criterion may have better reflected the reimbursement request compared with the trials of DUP in
adults (SOLO 1, SOLO 2, LIBERTY AD CHRONOS, and LIBERTY AD CAFÉ), which did not have the same clause regarding immunosuppressant therapies.3-7

The recommended dose of dupilumab is age- and weight-specific. In adolescents 12 to 17 years old who weigh < 60 kg, two subcutaneous injections of 200 mg of DUP should be administered as the loading dose during the first week, after which one 200 mg injection should be taken every other week.8 In adolescents who weigh ≥ 60 kg, and in all adults (≥ 18 years), the recommended loading dose is 600 mg of DUP (two 300 mg injections), followed by 300 mg every other week. At the submitted price of $959.94 for each of the 200 mg and 300 mg injections, the first-year cost of DUP is $25,918 per patient and the annual maintenance cost is $24,958 per patient. In the model, the sponsor assumed DUP treatment dosage was 200 mg (for adolescents < 60 kg) or 300 mg (for adolescents ≥ 60 kg and adults) every two weeks.1 No cost was associated with the use of topical therapy in the model.

The clinical outcomes of interest were QALYs and life-years. The economic analysis was undertaken over a lifetime time horizon (86 years) from the perspective of the public health care payer. A discount of 1.5% per annum was applied to both costs and outcomes.

**Model Structure**

The model structure included a short-term (one-year) phase for the 16- and 52-week assessments (based on the AD-1526, SOLO 1, SOLO 2, LIBERTY AD CHRONOS, and LIBERTY AD CAFÉ trials), and a lifetime model for the maintenance phase.1,3,6 The short-term phase was based on a decision tree (Figure 1) that modelled all patients as nonresponders until the first treatment response assessment of whether the Eczema and Severity Score Index (EASI) scores improved by ≥ 50% compared with baseline (EASI-50). The sponsor modelled week-16 efficacy outcomes from the AD-1526 trial at week 8 based on cumulative-time-to-response plots that suggested most patients who responded did so before 8 weeks.1,9 In the DUP arm, patients who responded to treatment stayed on DUP until 52 weeks, at which point patient responses were assessed according to data from the LIBERTY AD CHRONOS trial. All nonresponders were treated with SOC. If patients were deemed responders at weeks 16 and 52, they entered the response state for the respective treatment in a Markov state-transition model (Figure 2) of the maintenance phase. The Markov model incorporated a one-year cycle time to which a half-cycle correction was applied, and consisted of four health states: DUP + SOC treatment with response, SOC treatment with response, SOC treatment without response, and death. In the maintenance phase, patients were allowed to discontinue DUP and transition to either SOC treatment state. Patients in the SOC with response state could transition to the SOC without response state. Patients could transition from each of these states to an absorbing death state.

**Model Inputs**

In the base case, the patients’ baseline characteristics reflected the AD-1526 trial’s distribution of risk factors in adolescent patients.9 Patients entered the model at 14 years of age; 59% were male and 51% had a weight of < 60 kg (each received 200 mg injections of DUP until age 18, followed by 300 mg injections thereafter). The sponsor assumed that all patients independently administered the injections and were 100% compliant to treatment.

The clinical efficacy of DUP + SOC and SOC were obtained from the AD-1526 and LIBERTY AD CHRONOS trials.4,9 Response at 16 weeks was based on Study 1526 for both DUP + SOC (61.0%) and SOC (12.9%).9 For DUP + SOC, a conditional probability of sustaining the response for 52 weeks was modelled based on the sponsor-reported proportions of those who achieved a 16-week response and responders at week 52 from the CHRONOS study.3 Similarly, for SOC, the conditional probability was calculated for all SOC-treated patients given the proportions of responders at week 16 and
Maintenance of treatment effect beyond 52 weeks was based on clinical-expert feedback that suggested the probability of sustaining treatment response over time was much higher for DUP + SOC (98% in year 2 to 92% in year 5 and beyond) than for SOC (37% in year 2 to 0% in year 4 and beyond). A discontinuation rate of 6.3% per annum was derived from the SOLO trials.\(^\text{10}\)

The sponsor assumed that treatment did not affect mortality risk. Age- and sex-specific death rates, from the National Life Tables for Canada, were weighted by the cohort’s proportion of males and females and modelled annually.\(^\text{11}\)

Health-state utility values were collected (at weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, and 28) in the SOLO trials using EuroQol 5-Dimensions (EQ-5D) 3-Levels questionnaire values.\(^\text{5,6}\) Data from a subgroup of patients in the SOLO trial aged 18 to 25 were used as a proxy for adolescent patients (aged 14 to 18 years) and stratified according to treatment and whether patients were responders (i.e., DUP + SOC = \[\text{SOC} = \text{SOC}\]) or not (i.e., DUP + SOC = \[\text{SOC} = \text{SOC}\]). Covariates were identified and regression coefficients were applied to the baseline treatment-specific values based predominantly on observed data from the 1526 trial (except for the baseline EQ-5D utility score). When patients turned 19 years of age, data from the full SOLO trial were modelled by treatment and response status (responders: DUP + SOC = \[\text{SOC}\]; nonresponders: DUP + SOC = \[\text{SOC}\]). The model allowed for the use of results based on a regression of the adult population data. Caregiver-related utility gains for responders were incorporated as part of the base case, while impact on quality of life due to adverse events was not modelled.\(^\text{1}\)

The model included acquisition costs of DUP, health-state medical costs (by responder status), and the cost of treating adverse events. Drug costs for DUP were based on the sponsor’s submitted price at the dose regimen identified in the product monograph. Costs for all scheduled doses were incurred in accordance with an assumption of 100% treatment compliance, although a rationale or source for this approach was not provided. The sponsor excluded the cost of self-injection training with a nurse for one hour on the assumption that their planned patient-support program would provide such resources. The drugs that comprised SOC (types of topical therapies were not identified) were not costed to avoid issues of double-counting, as health state–specific costs were present in the model based on responder status. Nonresponders incurred a greater number of medical visits (e.g., to see a dermatologist and receive primary care) compared with responders. The frequency of resource use that the nonresponders and responders incurred reflected the opinions of clinical experts. Lastly, the sponsor modelled the cost of a dermatologist visit to treat a one-time injection-site reaction among DUP users, as well as for the treatment of adverse events each cycle. Patients taking either intervention were at risk of developing allergic conjunctivitis, infectious conjunctivitis, oral herpes, or a skin infection. All cost estimates were sourced from the Ontario Drug Formulary, Ontario Schedule of Benefits, Ontario Case Costing Initiative, and the Ontario Schedule of Benefits for Laboratory Services.\(^\text{12-14}\)

Summary of Sponsor’s Economic Evaluation Results

All analyses were run probabilistically (5,000 iterations for the base case and scenario analyses). The results were similar between the probabilistic and deterministic analyses. The probabilistic findings are presented below.

**Base-Case Results**

The sponsor’s base case comprised of the Health Canada–indicated population. In these results, DUP + SOC was associated with an additional $127,607 and 2.55 QALYs compared with SOC over the 86-year time horizon (Table 3). This resulted in an incremental cost-effectiveness ratio (ICER) of $50,133 per QALY gained for DUP + SOC compared to SOC.
The results were primarily driven by drug acquisition costs, which were partially offset by savings in medical costs (Table 12). The majority (96%) of the incremental QALYs for DUP + SOC were accrued during the extrapolation period (i.e., after 52 weeks of observed trial data). The sponsor’s base case was associated with a notable degree of decision uncertainty as DUP + SOC had a 49% chance of being the optimal intervention at a willingness-to-pay threshold of $50,000 per QALY.

To address the reimbursement request, the sponsor also estimated the cost-effectiveness of DUP in a subgroup of patients who were refractory to, or ineligible for, systemic immunosuppressant therapies. The ICER for DUP + SOC versus SOC was $52,168 per QALY gained (Table 13).

Table 3: Summary of the Sponsor’s Economic Evaluation Results

<table>
<thead>
<tr>
<th></th>
<th>Total costs ($)</th>
<th>Incremental cost of DUP + SOC ($)</th>
<th>Total QALYs</th>
<th>Incremental QALYs of DUP + SOC ($)</th>
<th>ICER ($ per QALY)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOC</td>
<td>358,555</td>
<td>Reference</td>
<td>23.67</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>DUP + SOC</td>
<td>486,163</td>
<td>127,607</td>
<td>26.22</td>
<td>2.55</td>
<td>$50,133</td>
</tr>
</tbody>
</table>

DUP = dupilumab; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year; SOC = standard of care.

Source: Sponsor’s pharmacoeconomic submission.

Note: The submitted results were based on the publicly available prices of the comparator treatments. Total expected life-years (43.04 years) were derived from the deterministic analysis, but likely do not differ between comparators given that the total expected QALYs estimated in the probabilistic analysis were similar (DUP + SOC = 26.22; SOC = 23.67).

Sensitivity and Scenario Analysis Results

The sponsor assessed several model features in probabilistic scenario analyses, as reported in Table 13. Three scenarios suggested a > 10% increase in the ICER. When the model population included the SOLO trial’s subgroup of adults whose mean age was 34 years, the ICER was $7,286 greater than the base-case estimate (scenario 11: $57,419 per QALY gained). The addition of patients who could no longer use systemic immunosuppressant therapies to this subgroup in another scenario produced a similar ICER (scenario 12: $57,991 per QALY). The greatest increase from the base-case estimate occurred when utility values were based on the sponsor’s unpublished study of EQ-5D data among children with AD. When the analysis undertook a societal perspective, the ICER decreased by approximately 30%.

CADTH Appraisal of the Sponsor’s Economic Evaluation

CADTH identified several key limitations to the sponsor’s analysis that have notable implications for the economic analysis:

- **Omission of relevant comparators**: In the Health Canada–indicated population, the current SOC for the treatment of AD in adolescents and adults includes the use of systemic immunosuppressants, such as methotrexate and cyclosporine. The benefits and costs of these widely used treatments were not included in the model. Systemic immunosuppressants are less expensive than DUP and more effective than SOC. The exclusion of relevant comparators from the analysis limits the assessment of the relative value of DUP + SOC in the Health Canada–indicated population. This limitation does not apply to the analysis for the reimbursement-request population, which included individuals who are refractory to or ineligible for systemic immunosuppressant therapies, for which SOC (i.e., topical therapy) is the only relevant comparator.
Given the lack of comparative clinical effectiveness data presented by the sponsor and the structure of the submitted economic model, CADTH was unable to conduct a reanalysis to assess this limitation.

- **The adolescent trial population was clinically different from the adult trial populations**: The sponsor used data from the AD-1526 trial to define the population’s baseline characteristics and treatment response at week 16. Study AD-1526 consisted of adolescents who had more severe AD than those in the studies of DUP in adults (see CADTH Clinical Report). Furthermore, in AD-1526, topical prescription therapies, and systemic immunosuppressants were reserved for use as rescue medication, even among members of the placebo group who otherwise applied only moisturizers throughout follow-up. In the adult studies, patients on DUP concomitantly used emollients (SOLO 1 and SOLO 2) or a medium-potency topical corticosteroid (LIBERTY AD CHRONOS and LIBERTY AD CAFE). As such, the use of AD-1526 data may better represent the sponsor’s reimbursement-request population. The combination of these data sources may limit the generalizability of the sponsor’s results to the indicated population given the inherent differences in the disease status of the population. Further implications of the differences in the patient populations are highlighted in a subsequent discussion of limitations.

  - CADTH considered alternate scenarios in which different efficacy assumptions were applied for the different populations.

- **The model lacked flexibility to assess relevant subgroups**: The trial data suggest that treatment effects differed depending on disease severity at baseline (see CADTH Clinical Report). This variation in effect was seen across the SOLO 1, SOLO 2, LIBERTY AD CHRONOS, and AD-1526 trials for both EASI scores improved by ≥ 75% compared with baseline (EASI-75) and Investigator’s Global Assessment outcomes, although the direction was not consistent across trials. These differences suggested the need to account for heterogeneity in DUP's efficacy outcomes through a subgroup analysis of DUP + SOC’s cost-effectiveness based on disease severity. Separate assessments of individuals with moderate AD and those with severe AD could not be undertaken with the available clinical information. Consequently, the cost-effectiveness of DUP + SOC in such subgroups remains unknown.

  - CADTH was unable to explore how the cost-effectiveness of DUP + SOC may differ in patients with moderate AD versus those with severe AD given the available information for the outcome of interest. CADTH conducted exploratory analyses to present estimates for an alternate outcome (EASI-75). The consistency in the results for the moderate and severe populations, despite the differences in treatment response at week 16 between the groups, suggests that the duration of effect between weeks 16 and 52 has a larger impact on the results. This finding introduces some additional uncertainty to the results.

- **Treatment-specific utility values were associated with methodological uncertainty**: Under current guidelines for the conduct of economic evaluations, utilities should reflect the health states within the model and should not be specific to treatment. No justification was provided to support the use of the treatment-specific utility values, which were derived using preference weights for the British population to obtain EQ-5D 3-Level outcomes. A mixed-model regression analysis of data from a subgroup of patients in the SOLO trial aged 18 to 25 were used as a proxy for adolescent patients. The utility estimate for respondents to DUP + SOC was also higher than the utility weight associated with response to SOC, a finding that the clinical expert consulted by CADTH did not consider to be reasonable. The methodology was associated with substantial uncertainty and introduced considerable bias in the estimated cost-effectiveness measures.
• CADTH used the utility weights estimated for patients on SOC in the SOLO trials to model the same utility weights for response and non-response in all patients, irrespective of treatment.4,5

• Utility estimates lacked face validity: CADTH identified three issues in the modelled utility estimates' face validity. First, the baseline utility value was lower than values previously reported for patients with moderate-to-severe AD by health technology assessment agencies (range: 0.64 to 0.70)16-18 and was based on a proxy population (18- to 25-year-olds from the SOLO trials).4,5 Second, the use of data from the two different sources (a proxy population to inform the utility values for adolescents aged 14 to 18 years and the full SOLO population for adults aged 19 years and older) resulted in an unrealistic decrease in utility for patients once they turned 19 years of age. Third, the utility weight assigned to patients with response on DUP + SOC was higher than the EQ-5D population norm among 18- to 24-year-olds in Canada (mean = 0.88; SD = 0.10), and did not appear to appropriately consider the differences in severity of disease at baseline between the adolescent and adult trial populations.9,19 The impact of using these estimates in the model likely overestimated DUP + SOC’s total expected QALYs.

• Inclusion of caregiver disutilities in base case: The sponsor included caregiver disutilities in the base case despite indicating that they adopted the public payer perspective. Per CADTH economic evaluation guidelines, such consequences are relevant to a societal, rather than a public payer, perspective, and should not have been considered in the base case.15 The inclusion of caregiver disutilities in the base case overestimated the total expected QALYs for DUP + SOC and underestimated the ICER for DUP + SOC versus SOC.

• Use of incorrect 52-week treatment outcomes from the LIBERTY AD CHRONOS trial: The CADTH clinical reviewers were unable to validate the efficacy measures that the sponsor reported were from the LIBERTY AD CHRONOS trial and were used to model treatment response outcomes at 52 weeks for both comparators. The use of data that could not be validated incorporated bias in the total QALYs estimated for each comparator.

• Durability of response beyond trial duration: The model included treatment-specific assumptions to incorporate the durability of treatment response. Based on expert opinion, the sponsor assumed utility gains in DUP + SOC responders were stable over time, but that short-term gains in utility among the SOC responders diminished rapidly such that, by year 4, all SOC responders returned to their baseline utility values, adjusted by age. The clinical expert consulted by CADTH advised that patients on SOC would not revert to the baseline utility by year 4. The expert also noted that responders to DUP + SOC will be less likely to continue topical therapy than responders to SOC, which may result in fewer patients maintaining treatment efficacy than was captured by the submitted model. Such treatment-specific assumptions appear to underestimate the absolute benefit of SOC and may overestimate that of DUP + SOC. Other health technology assessment agencies considered alternate assumptions regarding the duration of effect, which suggested a longer maintenance of benefit for patients receiving SOC.20

• Given the expert’s view that it is unlikely that SOC responders would lose all treatment benefits after year one, CADTH incorporated alternative waning assumptions for the SOC comparator based on the annual rate of rescue therapy or loss to follow-up in the
LIBERTY AD CHRONOS trial. Alternative assumptions were also tested in scenario analyses.

- **Resource use and costs did not reflect clinical practice in Canada:** The sponsor adopted a micro-level costing approach to model costs by treatment and response status based on expert-elicited frequencies of resource use. However, some treatment-specific frequencies did not align with Canadian clinical practice according to the clinical expert consulted by CADTH. For example, SOC responders incurred three visits to the dermatologist each year, whereas DUP + SOC responders incurred one. In Canada, patients who develop the same response to interventions for AD would likely incur the same health care costs irrespective of treatment type. Furthermore, this approach did not account for cost and resource use for patients who develop less than the expected level of response to treatment, such as additional follow-up assessments. The incorporation of expert-elicited frequencies of resource use appear to underestimate the total expected cost of DUP + SOC.
  - CADTH used annual health care costs incurred by patients with AD, by response status, obtained from published data.

- **Treatment response definition based on marginal response:** The sponsor’s definition of treatment response was based on achieving EASI-50, which represents the clinical outcome for defining relative treatment response (rather than complete response). The clinical expert consulted by CADTH for this review notes that, in Canada, the most common clinical outcome that dermatologists use to assess AD-related treatment response is EASI-75 after 16 weeks, but that in practice, patients who experienced an EASI improvement of 40% or greater would likely be continued on treatment for at least an additional six months.
  - CADTH implemented a scenario analysis in which treatment response was based on the EASI-75 sourced from the pooled SOLO trial data.

Additionally, the following key assumptions were made by the sponsor and have been appraised by CADTH (See Table 4).

### Table 4: Key Assumptions of the Submitted Economic Evaluation

<table>
<thead>
<tr>
<th>Sponsor’s key assumption</th>
<th>CADTH comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment with dupilumab included concomitant topical therapy.</td>
<td>Reasonable as dupilumab can be used with or without topical corticosteroids.</td>
</tr>
<tr>
<td>Efficacy (modelled as change in EASI score and utility weights) was assumed to occur at 8 weeks (halfway through the clinical assessment of 16 weeks).</td>
<td>The CADTH clinical expert noted that patients taking dupilumab are likely to develop AD-related changes soon after treatment onset.</td>
</tr>
<tr>
<td>No utility impacts associated with adverse events.</td>
<td>Reasonable as captured through treatment-related quality of life measures obtained throughout the dupilumab trials.</td>
</tr>
</tbody>
</table>

AD = atopic dermatitis; EASI = Eczema Area and Severity Index.

### CADTH Reanalyses of the Economic Evaluation

#### Base-Case Results

CADTH undertook reanalyses that addressed limitations within the model, as summarized in Table 5. CADTH could not fully address limitations associated with the lack of relevant comparators and treatment compliance.
CADTH undertook a stepped analysis, incorporating each change proposed in Table 5 to the sponsor’s base case to highlight the impact of each change in Table 6.
Table 6: Summary of the Stepped Analysis of the CADTH Reanalysis Results

<table>
<thead>
<tr>
<th>Stepped analysis</th>
<th>Drug</th>
<th>Total costs ($)</th>
<th>Total QALYs</th>
<th>ICER ($/QALYs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor’s base case</td>
<td>SOC^a</td>
<td>358,555</td>
<td>23.67</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>DUP + SOC</td>
<td>486,163</td>
<td>26.22</td>
<td>50,133</td>
</tr>
<tr>
<td>CADTH reanalysis 1</td>
<td>SOC^a</td>
<td>357,297</td>
<td>23.07</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>DUP + SOC</td>
<td>497,783</td>
<td>26.49</td>
<td>50,363</td>
</tr>
<tr>
<td>CADTH reanalysis 2</td>
<td>SOC^a</td>
<td>359,409</td>
<td>25.63</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>DUP + SOC</td>
<td>486,395</td>
<td>27.96</td>
<td>54,704</td>
</tr>
<tr>
<td>CADTH reanalysis 3</td>
<td>SOC^a</td>
<td>357,867</td>
<td>23.63</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>DUP + SOC</td>
<td>485,668</td>
<td>25.58</td>
<td>65,371</td>
</tr>
<tr>
<td>CADTH reanalysis 4</td>
<td>SOC^a</td>
<td>359,340</td>
<td>23.66</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>DUP + SOC</td>
<td>485,524</td>
<td>25.61</td>
<td>64,683</td>
</tr>
<tr>
<td>CADTH reanalysis 5</td>
<td>SOC^a</td>
<td>359,408</td>
<td>23.68</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>DUP + SOC</td>
<td>491,612</td>
<td>26.33</td>
<td>49,861</td>
</tr>
<tr>
<td>CADTH reanalysis 6</td>
<td>SOC^a</td>
<td>358,398</td>
<td>23.67</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>DUP + SOC</td>
<td>485,990</td>
<td>26.21</td>
<td>50,260</td>
</tr>
<tr>
<td>CADTH reanalysis 7</td>
<td>SOC^a</td>
<td>181,966</td>
<td>23.67</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>DUP + SOC</td>
<td>332,951</td>
<td>26.22</td>
<td>59,167</td>
</tr>
</tbody>
</table>

DUP = dupilumab; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-years; SOC = standard of care.

Note: The submitted results were based on the publicly available prices of the comparator treatments.

^a Reference product is least costly alternative.

The stepped analyses were combined in the CADTH base case. The probabilistic results of the CADTH base case included publicly available prices of the comparator treatments and reflected the Health Canada–indicated population (Table 7). DUP + SOC was $171,694 more costly and generated 1.26 additional QALYs than SOC. The ICER for DUP + SOC versus SOC was $136,025 per additional QALY gained. The likelihood that DUP + SOC represented the most cost-effective strategy was 0% if the willingness-to-pay threshold was $50,000 per QALY (or $100,000 per QALY).

Notably, 95% of DUP + SOC’s total incremental benefit (1.20 of 1.26 QALYS), compared to SOC, was accrued during the extrapolated period (Table 7).
Table 7: Disaggregated Summary of the CADTH Economic Evaluation Resultsa

<table>
<thead>
<tr>
<th>Parameter</th>
<th>DUP + SOC</th>
<th>SOC</th>
<th>Increment</th>
<th>Percentage (%) of total incrementb</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Discounted QALYs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>26.87</td>
<td>25.61</td>
<td>1.26</td>
<td></td>
</tr>
<tr>
<td>By health state</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decision tree</td>
<td>0.76</td>
<td>0.70</td>
<td>0.06</td>
<td>5.1</td>
</tr>
<tr>
<td>Maintenance treatment</td>
<td>5.77</td>
<td>0.00</td>
<td>5.77</td>
<td>457.8</td>
</tr>
<tr>
<td>Best supportive care without response</td>
<td>20.28</td>
<td>24.76</td>
<td>-4.48</td>
<td>-355.4</td>
</tr>
<tr>
<td>Best supportive care with response</td>
<td>0.06</td>
<td>0.15</td>
<td>-0.09</td>
<td></td>
</tr>
<tr>
<td><strong>Discounted costs ($)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>352,98</td>
<td>181,288</td>
<td>171,694</td>
<td></td>
</tr>
<tr>
<td>By cost category</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active treatment</td>
<td>201,631</td>
<td>0</td>
<td>201,631</td>
<td>117.4</td>
</tr>
<tr>
<td>Flare medication</td>
<td>983</td>
<td>1,031</td>
<td>-49</td>
<td>0.0</td>
</tr>
<tr>
<td>Other medical</td>
<td>148,835</td>
<td>179,352</td>
<td>-30,517</td>
<td>-17.8</td>
</tr>
<tr>
<td>Administration</td>
<td>40</td>
<td>0</td>
<td>40</td>
<td>0.0</td>
</tr>
<tr>
<td>Adverse event</td>
<td>1,493</td>
<td>905</td>
<td>588</td>
<td>0.3</td>
</tr>
<tr>
<td><strong>ICER</strong></td>
<td></td>
<td></td>
<td></td>
<td>136,025 per QALY gained</td>
</tr>
</tbody>
</table>

DUP = dupilumab; QALY = quality-adjusted life-year; SOC = standard of care.

Note: The submitted results were based on the publicly available prices of the comparator treatments.

*aThe CADTH base case incorporated treatment response outcomes at week 16 from the SOLO trials23 to estimate DUP + SOC’s cost-effectiveness versus SOC in the Health Canada—indicated population.

**Percentage of total incremental (e.g., the incremental difference within the decision tree is 0.06. When considered in the context of the total incremental difference of 1.26, this equates to 5.1% of the total increment; 0.06/1.26 = 0.051. The same calculation method was used for the other health states).

**Scenario Analysis Results**

CADTH undertook price-reduction analyses in the sponsor’s base case and in the CADTH base case, assuming proportional price reductions for DUP + SOC (Table 8). To achieve an ICER below $50,000 per QALY, a price reduction of 54% would be required. However, it should be noted that at this price reduction, there is an 52% likelihood that DUP + SOC is cost-effective.

Table 8: CADTH Price-Reduction Analyses

<table>
<thead>
<tr>
<th>Price reduction</th>
<th>ICERs for DUP + SOC vs. SOC ($ per QALY)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sponsor base case</td>
</tr>
<tr>
<td>No price reduction</td>
<td>50,133</td>
</tr>
<tr>
<td>10%</td>
<td>43,094</td>
</tr>
<tr>
<td>20%</td>
<td>36,082</td>
</tr>
<tr>
<td>30%</td>
<td>29,341</td>
</tr>
<tr>
<td>40%</td>
<td>22,090</td>
</tr>
<tr>
<td>50%</td>
<td>15,174</td>
</tr>
<tr>
<td>60%</td>
<td>8,250</td>
</tr>
</tbody>
</table>

DUP = dupilumab; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-years; SOC = standard of care; vs. = versus.

Note: The submitted results were based on the publicly available prices of the comparator treatments.
CADTH performed several analyses on alternate scenarios; including a reassessment of the reimbursement-request population, using EASI-75 as the definition of treatment response, use of the micro-level costing method, and testing alternate estimates of the percentage who sustained treatment response during the extrapolated period (Table 14). CADTH also undertook additional exploratory analyses to present estimates for an alternative outcome (EASI-75) (Table 16). However, the consistency in the results for the moderate and severe populations, despite the differences in treatment response at 16 weeks between the subgroups identified in the trials, suggests that the duration of effect between weeks 16 and 52 has a larger impact on the results.

To estimate DUP + SOC’s cost-effectiveness within the scope of the sponsor’s reimbursement request, CADTH incorporated AD-1526 data in a scenario analysis (scenario 1; Table 14). DUP + SOC generated additional costs ($156,469) and QALYs (1.17) compared with SOC. The ICER ratio of DUP + SOC versus SOC was $133,877 per QALY gained. The same price reduction was required to achieve an ICER below $50,000 per QALY (Table 15).

CADTH also assessed model features in probabilistic scenario analyses, as reported in Table 14. The ICER decreased by > 10% in the scenarios in which treatment response definition was based on the SOLO trials’ pooled EASI-75 outcomes. CADTH incorporated the sponsor’s micro-level costing approach, but revised it to have the same frequency of health care visits for all responders; and the percentage who sustained treatment response during the extrapolated period were based on the clinical expert’s estimates. The ICER did not change notably in scenarios that explored outcomes in the reimbursement-request population or the impacts of alternative estimates of the percentage who sustained treatment response during the extrapolated period, including the sponsor’s submitted values.

**Issues for Consideration**

- DUP was previously reviewed by CADTH for the treatment of adult patients with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The CADTH Canadian Drug Expert Committee recommended that DUP not be recommended for use, citing two key reasons. First, no evidence was available that compared DUP with other drugs commonly used in the treatment of AD. Second, there were several notable gaps in the clinical evidence regarding DUP, including data to assess the long-term safety of DUP, concerns with the generalizability of the trial results to patients who would be expected to use DUP in clinical practice, and an absence of efficacy and safety data for the use of DUP in patients for whom topical prescription therapies are not advisable. Furthermore, given differences in the model structure between the original and current submissions, the corresponding results appeared to differ notably for the adult population. However, CADTH noted that the sponsor did not address all of the issues identified as part of the current submission.

- As noted by the clinical expert consulted by this review, there is no clear and objective definition of response. The expert stated that while the EASI score is most likely to be used, several other outcomes (e.g., Investigator’s Global Assessment) are used as well.

- Although the Health Canada-approved indication is for DUP to be used as a second-line drug in the treatment of moderate-to-severe AD following inadequate control with topical therapies and as a first-line treatment in patients for whom topical therapies are not advisable, the clinical expert indicated it may in fact be used as a second- or third-line treatment after failing systemic therapy or phototherapy. However, the CADTH clinical review identified limitations with the indirect comparisons that precluded making any
conclusions regarding the comparative clinical effectiveness of DUP + SOC versus these therapies. As the sponsor’s model did not allow for this comparison, and clinical review could not reach conclusions on the comparative effectiveness, the potential cost-effectiveness of DUP when compared against these alternative therapies is unknown.

- The sponsor assumed that all patients administered DUP injections independently and were 100% compliant to DUP + SOC treatment. The clinical expert consulted by CADTH suggested that in practice, compliance would be less than 100%, particularly because adolescents would require the assistance of caregivers and are least likely to maintain topical therapy consistently. CADTH was unable to explore the impact of reduced compliance in the model, as this was assumed to affect costs and did not account for the effects on patient outcomes, i.e., treatment-utility or response.

**Overall Conclusions**

The CADTH appraisal of the sponsor’s base case suggests that the reported results were associated with uncertainty for several reasons. The sponsor’s estimation of the ICER for DUP + SOC was $50,133 per QALY gained (2.55 incremental QALYs, $127,607 incremental costs) compared with SOC. However, this result warranted careful interpretation due to the absence of relevant comparators, the inclusion of data from different trial populations that were then modelled as the same population (which limited the generalizability to the indicated population), the model’s inability to facilitate subgroup analysis by disease severity, the use of uncertain measures to approximate the durability of treatment response, the use of utility estimates that lacked face validity and included caregiver-related disutilities, and the use of frequencies of health resource use that were not reflective of Canadian practice.

After addressing these issues in the CADTH reanalysis as comprehensively as possible, the decision uncertainty surrounding DUP + SOC’s relative value over SOC was substantial across the Health Canada–indicated and reimbursement-request populations. In the CADTH base case, which reflected the indicated population, the ICER for DUP + SOC versus SOC was $136,025 per QALY gained. The corresponding ICER in the scenario analysis that addressed the reimbursement-request population was similar, at $133,877 per QALY gained. The probability that DUP + SOC represented the optimal strategy was 0% at willingness-to-pay thresholds of $50,000 and $100,000 per QALY in both analyses. A reduction of 54% in DUP’s price was required to improve its cost-effectiveness, relative to SOC, in both populations and generate an ICER of less than $50,000 per QALY (indicated: $49,648 per QALY gained; reimbursement request: $48,681 per QALY gained).

Nonetheless, the results of the reanalysis, which were based on publicly available prices, remain uncertain as multiple limitations could not be addressed. CADTH was unable to assess the cost-effectiveness of DUP + SOC compared to alternative comparators that are presently used by patients with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies; nor was it possible to determine how DUP’s cost-effectiveness differed in patients with moderate AD versus those with severe AD. Results of additional scenario and exploratory analyses highlighted that the durability of effect between weeks 16 and 52 is a key driver of the model and has a greater impact than that of initial treatment response.
Appendix 1: Cost Comparison Table

The comparators presented in Table 9 have been deemed to be appropriate based on feedback from clinical experts. Comparators may be recommended (appropriate) practice or actual practice. Existing product listing agreements are not reflected in the table and as such, may not represent the actual costs to public drug plans.

Table 9: CADTH Cost Comparison Table for Systemic Treatments for Atopic Dermatitis

<table>
<thead>
<tr>
<th>Drug/comparator</th>
<th>Strength</th>
<th>Dosage form</th>
<th>Price ($)</th>
<th>Recommended dosage</th>
<th>Cost per day ($)</th>
<th>Cost per course ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dupilumab (Dupixent)</td>
<td>200 mg/1.14 mL, 300 mg/2 mL</td>
<td>Pre-filled syringe</td>
<td>$959.9350$</td>
<td>Adults: 600 mg as an initial dose, followed by 300 mg every two weeks &lt;br&gt; Adolescents &lt; 60 kg: 400 mg as an initial dose, followed by 200 mg every two weeks &lt;br&gt; Adolescents ≥ 60 kg: 600 mg as an initial dose, followed by 300 mg every two weeks</td>
<td>First year: 68 &lt;br&gt; Each subsequent year: 71</td>
<td>First year: 25,918 &lt;br&gt; Each subsequent year: 24,958</td>
</tr>
<tr>
<td>Azathioprine (generic)</td>
<td>50 mg</td>
<td>Tablet</td>
<td>0.2405</td>
<td>Pediatric: 1.0 to 4.0 mg/kg per day for 24 weeks &lt;br&gt; Adult: 1.0 to 3.0 mg/kg per day for 24 weeks</td>
<td>Pediatric: 0.24 to 0.96&lt;sup&gt;a&lt;/sup&gt; &lt;br&gt; Adult: 0.24 to 0.96&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Pediatric: 40 to 162 &lt;br&gt; Adult: 40 to 162</td>
</tr>
<tr>
<td>Cyclosporine (generic)</td>
<td>10 mg, 25 mg, 50 mg, 100 mg</td>
<td>Caplet</td>
<td>0.6520, 0.9952, 1.9400, 3.8815</td>
<td>Pediatric: 3.0 to 6.0 mg/kg per day for 24 weeks &lt;br&gt; Adult: 150 to 300 mg per day for 24 weeks</td>
<td>Pediatric: 3.88 to 11.64&lt;sup&gt;c&lt;/sup&gt; &lt;br&gt; Adult: 7.76 to 19.56&lt;sup&gt;c&lt;/sup&gt;</td>
<td>Pediatric: 652 to 2,957 &lt;br&gt; Adult: 1,304 to 3,286</td>
</tr>
<tr>
<td>Methotrexate (generic)</td>
<td>2.5 mg</td>
<td>Tablet</td>
<td>0.6325</td>
<td>Pediatric: 0.2 to 0.7 mg/kg per week for 24 weeks &lt;br&gt; Adult: 7.5 to 25 mg per week for 24 weeks</td>
<td>Pediatric: 2.28 to 7.97&lt;sup&gt;c&lt;/sup&gt; per week &lt;br&gt; Adult: 1.90 to 6.33 per week</td>
<td>Pediatric: 55 to 191 &lt;br&gt; Adult: 46 to 152</td>
</tr>
<tr>
<td>Mycophenolate mofetil</td>
<td>250 mg, 500 mg</td>
<td>Caplet</td>
<td>0.3712, 0.7423</td>
<td>Pediatric: 30.0 to 50.0 mg/kg per day for 24 weeks &lt;br&gt; Adult: 1.0 to 1.5 g twice daily for 24 weeks</td>
<td>Pediatric: 0.50 to 3.34&lt;sup&gt;c&lt;/sup&gt; &lt;br&gt; Adult: 2.23 to 2.97</td>
<td>Pediatric: 84 to 561 &lt;br&gt; Adult: 374 to 499</td>
</tr>
</tbody>
</table>

<sup>Abbreviations: <br>a: Pediatric <br>c: Adult</sup>
### Other treatments for adults not specifically indicated for the treatment of atopic dermatitis

<table>
<thead>
<tr>
<th>Drug/comparator</th>
<th>Strength</th>
<th>Dosage form</th>
<th>Price ($)</th>
<th>Recommended dosage</th>
<th>Cost per day ($)</th>
<th>Cost per course ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acitretin (Soriatane)</td>
<td>10 mg</td>
<td>Caplet</td>
<td>1.2965</td>
<td>10 to 50 mg once daily, maximum of 75 mg once daily for 24 weeks</td>
<td>1.30 to 6.83</td>
<td>218 to 1,148</td>
</tr>
<tr>
<td></td>
<td>25 mg</td>
<td></td>
<td>2.2770</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ailretinoin (Toctino)</td>
<td>10 mg</td>
<td>Caplet</td>
<td>21.9900</td>
<td>30 mg once daily, dose may be reduced to 10 mg if unacceptable side effects for 24 weeks</td>
<td>21.99</td>
<td>3,694</td>
</tr>
<tr>
<td></td>
<td>30 mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apremilast (Otezla)</td>
<td>10 mg/20 mg</td>
<td>Tablet</td>
<td>19.5715&lt;sup&gt;b&lt;/sup&gt;</td>
<td>30 mg twice daily, starting with titration pack (27 tablet kit titrating from 10 mg once daily to 30 mg twice daily)</td>
<td>19.57 to 39.14</td>
<td>First year: 14,268</td>
</tr>
<tr>
<td></td>
<td>30 mg</td>
<td></td>
<td></td>
<td></td>
<td>Each subsequent year: 14,287</td>
<td></td>
</tr>
<tr>
<td>Ustekinumab (Stelara)</td>
<td>45 mg/0.5 mL</td>
<td>Pre-filled syringe</td>
<td>4593.1400</td>
<td>45 mg at weeks 0 and 4 and then every 12 weeks thereafter, 90 mg may be used for patients &gt; 100 kg in weight</td>
<td>54.53</td>
<td>First year: 27,559</td>
</tr>
<tr>
<td></td>
<td>90 mg/1 mL</td>
<td></td>
<td></td>
<td></td>
<td>Each subsequent year: 19,904 to 39,807</td>
<td></td>
</tr>
</tbody>
</table>

Note: Unit prices of medications are taken from the Ontario Drug Benefit Formulary<sup>12</sup> (accessed October 2019), unless otherwise indicated. Recommended doses from respective product monographs, unless otherwise indicated. Annual period assumes 52 weeks, or 13 × 4 weeks per year (365 days for all comparators).

Note: According to the CADTH clinical expert consulted for this review, retinoids are primarily used to treat hand dermatitis in adults, not in adolescents.

<sup>a</sup> Sponsor’s submitted price for each dosage.<br><sup>b</sup> IQVIA Delta PA<sup>13</sup> wholesale price (retrieved January 2019).<br><sup>c</sup> Assumes child weight of 45 kg.<br><sup>d</sup> Assumes adult weight of 70 kg.

In addition, according to the clinical expert consulted as part of this review, the following topical treatments and phototherapy from the 2014 American Academy of Dermatology’s Guidelines of Care for the Management of Atopic Dermatitis<sup>25,26</sup> may be used to treat moderate-to-severe AD in adolescents and adults despite not being indicated (Table 10).

### Table 10: CADTH Cost Comparison Table for Topical Treatments for Atopic Dermatitis

<table>
<thead>
<tr>
<th>Drug/comparator</th>
<th>Strength</th>
<th>Package size</th>
<th>Dosage form</th>
<th>Price per gram ($)</th>
<th>Recommended dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Topical corticosteroids</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aminonide (generics)</td>
<td>0.1%</td>
<td>60 g tube 60 mL bottle 60 g tube</td>
<td>Cream Lotion Ointment</td>
<td>0.1955 0.2997&lt;sup&gt;a&lt;/sup&gt; 0.3069&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Thin amount to affected area twice daily, max 5 days on face, axillae, scrotum or scalp, two to three weeks elsewhere</td>
</tr>
<tr>
<td></td>
<td></td>
<td>50 g tube 75 mL bottle 50 g tube</td>
<td>Cream Foam Lotion Ointment</td>
<td>0.2048 1.5746&lt;sup&gt;b&lt;/sup&gt; 0.1980 0.5186</td>
<td>Thin film to affected area twice daily, duration of therapy varies; need should be reassessed at least every 4 weeks</td>
</tr>
<tr>
<td>Betamethasone dipropionate (generic)</td>
<td>0.05%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>450 g jar 30 mL, 60 mL bottles 450 g jar</td>
<td>Cream Lotion Ointment</td>
<td>0.0889 0.3125 0.0889</td>
<td>No recommended daily dose; use as directed by clinicians</td>
</tr>
<tr>
<td>Drug/comparator</td>
<td>Strength</td>
<td>Package size</td>
<td>Dosage form</td>
<td>Price per gram ($)</td>
<td>Recommended dosage</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>---------</td>
<td>-----------------------------------------------------------------------------</td>
<td>---------------------</td>
<td>--------------------</td>
<td>-----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Clobetasol propionate (generic)</td>
<td>0.05%</td>
<td>15 g, 50 g tubes, 450 g jar 15 g, 50 g tubes</td>
<td>Cream, Ointment</td>
<td>0.2279</td>
<td>Thin amount to affected area twice daily; weekly application should not exceed 50 g, and limited to two consecutive weeks</td>
</tr>
<tr>
<td>Desonide (generic)</td>
<td>0.05%</td>
<td>15 g, 60 g tubes, 454 g jar 60 g tube</td>
<td>Cream, Ointment</td>
<td>0.2650</td>
<td>Thin amount to affected area twice daily; may be increased in refractory cases</td>
</tr>
<tr>
<td>Desoximetasone (Topicort)</td>
<td>0.25%</td>
<td>20 g, 60 g tubes, 60 g tube 15 g, 60 g tubes</td>
<td>Cream, Ointment, Gel</td>
<td>0.7340</td>
<td>Thin amount to affected area twice daily</td>
</tr>
<tr>
<td></td>
<td>0.25%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.5%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluocinonide (Lyderm, Lidex)</td>
<td>0.05%</td>
<td>15 g, 60 g tubes, 400 g jar 15 g, 60 g tubes</td>
<td>Cream, Gel, Ointment</td>
<td>0.2378</td>
<td>Thin amount to affected area twice daily; weekly application should not exceed 45 g and limited to two weeks</td>
</tr>
<tr>
<td>Fluocinonide (Tiamol)</td>
<td>0.05%</td>
<td>25 g tube 100 g jar</td>
<td>Emol Cream</td>
<td>0.1980</td>
<td>Thin amount two to four times daily</td>
</tr>
<tr>
<td>Halobetasol propionate (Ultravate)</td>
<td>0.05%</td>
<td>15 g, 50 g tubes, 50 g tube</td>
<td>Cream, Ointment</td>
<td>1.1130</td>
<td>Thin amount to affected area twice daily; limited to 50 g weekly and two weeks without re-evaluation</td>
</tr>
<tr>
<td>Hydrocortisone (various)</td>
<td>1.0%</td>
<td>45 g tube 60 mL bottle</td>
<td>Cream, Lotion</td>
<td>0.1718</td>
<td>No recommended daily dose; use as directed by clinicians</td>
</tr>
<tr>
<td></td>
<td>1.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.5%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.5%</td>
<td>15 g tube 454 g jar</td>
<td>Ointment</td>
<td>0.1400</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.0%</td>
<td></td>
<td></td>
<td>0.0390</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone acetate</td>
<td>0.5%</td>
<td>15 g, 30 g tubes 28.4 g tube</td>
<td>Cream, Ointment</td>
<td>0.2056</td>
<td>Twice-daily application is generally recommended initially; intermittent use 1 to 2 times per week on areas that commonly flare for maintenance therapy</td>
</tr>
<tr>
<td></td>
<td>1.0%</td>
<td></td>
<td></td>
<td>0.4158</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone valerate (Hydroval)</td>
<td>0.2%</td>
<td>15 g, 45 g, 60 g tubes 15 g, 60 g tubes</td>
<td>Cream, Ointment</td>
<td>0.1313</td>
<td>Small amount to affected area twice daily; discontinue as soon as lesions heal or if no response</td>
</tr>
<tr>
<td>Mometasone furoate (generic)</td>
<td>0.1%</td>
<td>15 g, 50 g tubes 15 g, 50 g tubes</td>
<td>Cream, Ointment</td>
<td>0.5542</td>
<td>Thin film to affected areas twice daily</td>
</tr>
<tr>
<td></td>
<td>0.2%</td>
<td></td>
<td></td>
<td>0.2252</td>
<td></td>
</tr>
<tr>
<td>Triamcinolone acetonide (various)</td>
<td>0.1%</td>
<td>30 g tube 15 g tube</td>
<td>Cream, Ointment</td>
<td>0.0533</td>
<td>No recommended daily dose; use as directed by clinicians</td>
</tr>
<tr>
<td>Drug/comparator</td>
<td>Strength</td>
<td>Package size</td>
<td>Dosage form</td>
<td>Price per gram ($)</td>
<td>Recommended dosage</td>
</tr>
<tr>
<td>------------------------------</td>
<td>----------</td>
<td>--------------</td>
<td>-------------</td>
<td>--------------------</td>
<td>------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Topical calcineurin inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pimecrolimus (Elidel)</td>
<td>1%</td>
<td>10 g, 30 g tubes</td>
<td>Cream</td>
<td>2.4157</td>
<td>Thin layer to affected area twice daily; discontinue when resolved or after three weeks if no improvement or exacerbation</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>0.03%</td>
<td>30 g tube</td>
<td>Cream</td>
<td>2.3740</td>
<td>Thin layer to affected area twice daily; discontinue after six weeks if no improvement or exacerbation</td>
</tr>
<tr>
<td></td>
<td>0.10%</td>
<td></td>
<td></td>
<td>2.5397</td>
<td></td>
</tr>
<tr>
<td><strong>Phosphodiesterase type-4 inhibitor</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crisaborole (Eucrisa)</td>
<td>2%</td>
<td>60 g tube</td>
<td>Ointment</td>
<td>2.3000*</td>
<td>Thin layer to affected area twice daily</td>
</tr>
<tr>
<td><strong>Phototherapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ultraviolet light therapy</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>7.85 per treatment*</td>
<td>3 to 5 treatments per weekf</td>
</tr>
</tbody>
</table>

*emol = emollient; NA = not available.

* Saskatchewan Formulary list price27 (December 2019).
* Alberta Formulary list price26 (December 2019).
* British Columbia Formulary list price29 as reported by IQVIA Delta PA (January 2019).
* Crisaborole received a recommendation of do not reimburse from the CADTH Canadian Drug Expert Committee in March 2019 for treatment of mild-to-moderate AD in patients two years of age and older who have failed or are intolerant to a topical corticosteroid treatment.30,31
* Minimum frequency of phototherapy sessions required per week for successful maintenance as well as length of maintenance period varies tremendously between individuals.25,26

Source: Ontario Drug Benefit Formulary list prices14 unless otherwise indicated, recommended doses from respective product monographs unless otherwise indicated.
## Appendix 2: Submission Quality

### Table 11: Submission Quality

<table>
<thead>
<tr>
<th>Population is relevant, with no critical intervention missing, and no relevant outcome missing.</th>
<th>Yes</th>
<th>No</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐</td>
<td>☒</td>
<td>The sponsor included one relevant comparator, i.e., standard of care, but was missing several others. The population had limited generalizability to the indicated population. See “CADTH Appraisal of the Sponsor’s Economic Evaluation” for details.</td>
<td></td>
</tr>
</tbody>
</table>

| Model has been adequately programmed and has sufficient face validity. | ☒ | ☐ | The model was generally adequately programmed. |

| Model structure is adequate for the decision problem. | ☒ | ☐ | While the model structure was adequate for the decision problem, the chosen structure lacked the flexibility to capture the waxing and waning nature of atopic dermatitis. The model assumed that patients remaining on DUP + SOC treatment were constantly responding, and that treatment stopped immediately from the point in time that response was lost. A model that considered severity should have been presented. See “CADTH Appraisal of the Sponsor’s Economic Evaluation” for details. |

| Data incorporation into the model has been done adequately (e.g., parameters for probabilistic analysis). | ☒ | ☐ | The model varied most parameters relevant to the decision problem in a probabilistic analysis. For example, parameter distributions were not assigned to the resource-use event rates and incidence of adverse events, which were modelled as point estimates. Also, the model did not account for health care costs incurred by patients who develop a marginal treatment response. |

| Parameter and structural uncertainty were adequately assessed; analyses were adequate to inform the decision problem. | ☒ | ☐ | The model sufficiently captured parameter and structural uncertainty, with some exceptions. Measures of relative risk and corresponding standard errors were calculated incorrectly. Also, the model also did not capture the effects of treatment compliance adequately (see “CADTH Appraisal of the Sponsor’s Economic Evaluation”). |

| The submission was well organized and complete; the information was easy to locate (clear and transparent reporting; technical documentation available in enough details). | ☒ | ☐ | The report was generally coherent, but had notable gaps in the information it presented about the model. For instance, the report did not define topical therapies in standard of care and lacked adequate detail on the source of select model inputs (e.g., estimates used to derive the “relative risk” of sustained treatment response until week 52). Furthermore, the report did not provide justification for the use of certain formulas for the DUP + SOC comparator and others for the SOC comparator (e.g., approach for modelling the percentage who sustained a 52-week response). |

DUP = dupilumab; SOC = standard of care.
Appendix 3: Additional Information on the Submitted Economic Evaluation

Figure 1: Decision Tree

Figure 2: Markov Structure

AD = atopic dermatitis; BSC = best supportive care; DUP Q2W = dupilumab every 2 weeks.
Source: Sponsor’s pharmacoeconomic submission.

Figure 1: Decision Tree

Figure 2: Markov Structure

Trt. = treatment; BSC = best supportive care.
Source: Sponsor’s pharmacoeconomic submission.
Detailed Results of the Sponsor’s Submission

Table 12: Probabilistic Results of Sponsor’s Base-Case Analysis

<table>
<thead>
<tr>
<th>Parameter</th>
<th>DUP + SOC</th>
<th>SOC</th>
<th>Increment</th>
<th>Percentage (% of total increment)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discounted QALYs Total</td>
<td>26.22</td>
<td>23.67</td>
<td>2.55</td>
<td></td>
</tr>
<tr>
<td>By health state</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decision tree</td>
<td>0.83</td>
<td>0.72</td>
<td>0.11</td>
<td>4.3</td>
</tr>
<tr>
<td>Maintenance treatment</td>
<td>6.11</td>
<td>0.00</td>
<td>6.11</td>
<td>239.6</td>
</tr>
<tr>
<td>Best supportive care without response</td>
<td>19.26</td>
<td>22.89</td>
<td>−3.63</td>
<td>−142.4</td>
</tr>
<tr>
<td>Best supportive care with response</td>
<td>0.03</td>
<td>0.06</td>
<td>−0.03</td>
<td>−1.2</td>
</tr>
<tr>
<td>Discounted costs ($)</td>
<td>486,163</td>
<td>358,555</td>
<td>127,607</td>
<td></td>
</tr>
<tr>
<td>By cost category</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active treatment</td>
<td>177,333</td>
<td>0</td>
<td>177,333</td>
<td>139.0</td>
</tr>
<tr>
<td>Flare medication</td>
<td>985</td>
<td>1,027</td>
<td>−42</td>
<td>0.0</td>
</tr>
<tr>
<td>Other medical</td>
<td>306,375</td>
<td>356,622</td>
<td>−50,247</td>
<td>39.4</td>
</tr>
<tr>
<td>Administration</td>
<td>40</td>
<td>0</td>
<td>40</td>
<td>0.0</td>
</tr>
<tr>
<td>Adverse event</td>
<td>1,430</td>
<td>906</td>
<td>524</td>
<td>0.4</td>
</tr>
</tbody>
</table>

Incremental cost-effectiveness ratio $50,133 per QALY gained

DUP = dupilumab; QALY = quality-adjusted life-year; SOC = standard of care.

Note: Total expected life-years (43.04 years) were derived from the deterministic analysis, but likely do not differ between comparators given that the total expected QALYs that were estimated in the probabilistic analysis were similar (DUP + SOC = 26.22; SOC = 23.67).

Source: Sponsor’s pharmacoeconomic submission.

Table 13: Probabilistic Results of Sponsor’s Scenario Analyses

<table>
<thead>
<tr>
<th>Scenario</th>
<th>ICER ($ per QALY)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1  Baseline utility values based on sponsor’s unpublished study of EQ-5D data among children with AD</td>
<td>60,893</td>
</tr>
<tr>
<td>2  Discount rate of 0%</td>
<td>49,191</td>
</tr>
<tr>
<td>3  Discount rate of 3%</td>
<td>50,400</td>
</tr>
<tr>
<td>4  Included cost for self-injection training with a nurse for one hour</td>
<td>49,902</td>
</tr>
<tr>
<td>5  Patients who could no longer use systemic immunosuppressant therapies</td>
<td>52,168</td>
</tr>
<tr>
<td>6  Rate of discontinuing dupilumab use was 0%</td>
<td>50,065</td>
</tr>
<tr>
<td>7  Rate of discontinuing dupilumab use was 12.3%</td>
<td>49,922</td>
</tr>
<tr>
<td>8  Response definition was based on EASI-50 and DLQI ≥ 4</td>
<td>51,341</td>
</tr>
<tr>
<td>9  Response definitions was based on EASI-75</td>
<td>50,876</td>
</tr>
<tr>
<td>10 Societal perspective</td>
<td>35,778</td>
</tr>
<tr>
<td>11 SOLO trial’s subgroup of adults whose mean age was 34 years</td>
<td>57,419</td>
</tr>
<tr>
<td>12 SOLO trial’s subgroup of adults whose mean age was 34 years and all patients who could no longer use systemic immunosuppressant therapies</td>
<td>57,991</td>
</tr>
<tr>
<td>13 Sustained response only among patients taking dupilumab plus standard of care</td>
<td>49,178</td>
</tr>
<tr>
<td>14 Time horizon was 10 years</td>
<td>50,479</td>
</tr>
<tr>
<td>15 Time horizon was 5 years</td>
<td>51,918</td>
</tr>
</tbody>
</table>

AD = atopic dermatitis; DLQI = Dermatology Life Quality Index; EASI-50 = Eczema Area and Severity Index score improvement from baseline ≥ 50%; EASI-75 = Eczema Area and Severity Index score improvement from baseline ≥ 75%; EQ-5D = EuroQol 5-Dimensions; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year.

Source: Sponsor’s pharmacoeconomic submission.
Appendix 4: Additional Details on the CADTH Reanalyses and Sensitivity Analyses of the Economic Evaluation

Scenario Analyses

Table 14: Probabilistic Results of the CADTH Scenario Analyses

<table>
<thead>
<tr>
<th>Scenario</th>
<th>ICER ($/QALY)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1  Treatment response outcomes at week 16 sourced from AD-1526 to capture the reimbursement-request population</td>
<td>133,877</td>
</tr>
<tr>
<td>2  Treatment response definition based on the SOLO trials' pooled EASI-75 outcomes$\textsuperscript{33}</td>
<td>120,738</td>
</tr>
<tr>
<td>3  Incorporated micro-costing approach based on same number of dermatology visits for all responders</td>
<td>115,148</td>
</tr>
<tr>
<td>4  Sponsor’s submitted estimates of the percentage who sustained treatment response during extrapolated period in DUP + SOC and SOC</td>
<td>135,434</td>
</tr>
<tr>
<td>5  Percentage who sustained treatment response during the extrapolated period among patients on DUP + SOC (year 2: 90%; year 3: 80%; year 4: 70%; year 5+: 60%)</td>
<td>146,608</td>
</tr>
<tr>
<td>6  Clinical expert’s estimates of the percentage who sustained treatment response during extrapolated period in DUP + SOC (year 2: 90%; year 3: 80%; year 4: 70%; year 5+: 60%) and SOC (year 2: 80%; year 3: 60%; year 4: 40%; year 5+: 20%)</td>
<td>150,854</td>
</tr>
</tbody>
</table>

DUP = dupilumab; EASI-75 = Eczema Area and Severity Index score improvement from baseline ≥ 75%; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year; SOC = standard of care.

Table 15: Additional CADTH Price-Reduction Analyses – Reimbursement-Request Population

<table>
<thead>
<tr>
<th>Price reduction</th>
<th>ICERs for DUP + SOC vs. SOC ($ per QALY)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sponsor base case</td>
</tr>
<tr>
<td>No price reduction</td>
<td>50,133</td>
</tr>
<tr>
<td>10%</td>
<td>43,094</td>
</tr>
<tr>
<td>20%</td>
<td>36,082</td>
</tr>
<tr>
<td>30%</td>
<td>29,341</td>
</tr>
<tr>
<td>40%</td>
<td>22,090</td>
</tr>
<tr>
<td>50%</td>
<td>15,174</td>
</tr>
<tr>
<td>60%</td>
<td>8,250</td>
</tr>
</tbody>
</table>

DUP = dupilumab; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year; SOC = standard of care; vs. = versus.

Note: The submitted results were based on the publicly available prices of the comparator treatments.

$^a$CADTH scenario 1 incorporated treatment response outcomes at week 16 from the AD-1526 trial$^5$ to estimate DUP + SOC’s cost-effectiveness vs. SOC in the reimbursement-request population.
Table 16: Probabilistic results of the CADTH Exploratory Analyses by Disease Severity

<table>
<thead>
<tr>
<th>Scenario</th>
<th>ICER ($ per QALY)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1  Treatment response definition based on the SOLO 1 trial’s EASI-75 outcomes at week 16 and the CHRONOS trial’s EASI-75 outcomes at week 52; restricted to patients with moderate AD</td>
<td>121,639</td>
</tr>
<tr>
<td>2  Treatment response definition based on the SOLO 1 trial’s EASI-75 outcomes at week 16 and the CHRONOS trial’s EASI-75 outcomes at week 52; restricted to patients with severe AD</td>
<td>121,306</td>
</tr>
<tr>
<td>3  Treatment response definition based on the CHRONOS trial’s EASI-75 outcomes at week 16 and 52; restricted to patients with moderate AD</td>
<td>123,220</td>
</tr>
<tr>
<td>4  Treatment response definition based on the CHRONOS trial’s EASI-75 outcomes at week 16 and 52; restricted to patients with severe AD</td>
<td>118,723</td>
</tr>
</tbody>
</table>

AD = atopic dermatitis; EASI-75 = Eczema Area and Severity Index score improvement from baseline ≥ 75%; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year.

Note: Treatment effects derived from Appendix 3 in the CADTH Clinical Report.
References


2. CDR submission: Dupixent (dupilumab), 300 mg & 200 mg injection [CONFIDENTIAL sponsor's submission]. Mississauga (ON): Sanofi Genzyme; 2019 Oct 22.

3. Clinical Study Report: R668-AD-1424. A phase 3 study investigating the efficacy, safety, and tolerability of dupilumab administered to adult patients with severe atopic dermatitis who are not adequately controlled with or are intolerant to oral cyclosporine a, or when this treatment is not medically advisable [CONFIDENTIAL internal sponsor's report]. Tarrytown (NY): Regeneron Pharmaceuticals, Inc.; 2017 May 11.


21. AWARE costing (Canada data) [CONFIDENTIAL sponsor internal report]. Mississauga (ON): Sanofi Genzyme.


